From a business perspective, Venezia said he doesnt begrudge IBX for making this decision or the pharmaceutical companies from making money
Retatrutide Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors, offering a broader metabolic response compared to tirzepatide
In decompensated cirrhosis, patients are symptomatic, due to significant fibrotic changes, and present with one or more of the following: ascites, jaundice, hepatic encephalopathy, or variceal hemorrhage.(2) Of note cirrhosis is one of five conditions encompassed by the broad category metabolic dysfunction-associated steatotic liver disease (MASLD).(3) Background: How GLP-1 RAs Work and Potential Cirrhosis Benefit GLP-1 RAs stimulate prandial insulin secretion, limiting glucagon production, slowing gastric motility and increasing satiety
Patients should follow all post-operative instructions to promote optimal healing
none of the patients with significant RGV reported symptoms on the day of the procedure
-pj.jpg)
